RecruitingPhase 3NCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alexion Pharmaceuticals, Inc.
Intervention: Ravulizumab(drug)
Enrollment: 24 enrolled
Eligibility: 2-18 years · All sexes
Timeline: 2025 – 2029

Study locations (13)

Research Site, Palo Alto, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Beijing, China
Research Site, Shanghai, China
Research Site, Genova, Italy
Research Site, Roma, Italy
Research Site, Torino, Italy
Research Site, Wakayama, Japan
Research Site, Seoul, South Korea
Research Site, Barcelona, Spain
Research Site, Seville, Spain
Research Site, Taipei, Taiwan
Research Site, Taoyuan District, Taiwan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07024563 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials